Heron Therapeuti (HRTX)vsJohnson & Johnson (JNJ)
HRTX
Heron Therapeuti
$0.36
+13.52%
HEALTHCARE · Cap: $55.85M
JNJ
Johnson & Johnson
$258.80
-2.30%
HEALTHCARE · Cap: $648.67B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 64677% more annual revenue ($97.93B vs $151.18M). JNJ leads profitability with a 21.5% profit margin vs -22.5%. JNJ earns a higher WallStSmart Score of 59/100 (C).
HRTX
Avoid29
out of 100
Grade: F
JNJ
Buy59
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for HRTX.
Margin of Safety
-89.2%
Fair Value
$141.39
Current Price
$258.80
$117.41 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Mega-cap, among the largest globally
Every $100 of equity generates 25 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 29.2%
Generating 3.4B in free cash flow
Areas to Watch
Trading at 11.9x book value
1.3% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Premium valuation, high expectations priced in
Weak financial health signals
Expensive relative to growth rate
Earnings declined 0.9%
Comparative Analysis Report
WallStSmart ResearchBull Case : HRTX
HRTX has a balanced fundamental profile.
Bull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.5% and operating margin at 29.2%.
Bear Case : HRTX
The primary concerns for HRTX are Price/Book, Revenue Growth, EPS Growth. Debt-to-equity of 21.48 is elevated, increasing financial risk.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, Piotroski F-Score, PEG Ratio.
Key Dynamics to Monitor
HRTX profiles as a turnaround stock while JNJ is a mature play — different risk/reward profiles.
HRTX carries more volatility with a beta of 1.61 — expect wider price swings.
JNJ is growing revenue faster at 6.6% — sustainability is the question.
JNJ generates stronger free cash flow (3.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 29/100), backed by strong 21.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Heron Therapeuti
HEALTHCARE · BIOTECHNOLOGY · USA
Heron Therapeutics, Inc., a biotechnology company, is dedicated to developing treatments to address unmet medical needs. The company is headquartered in San Diego, California.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?